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Abstract The prevalence of cardiac cachexia in chronic
heart failure is approximately 5% to 15% and 18-month
mortality rates can reach 50%. Treatment with angiotensin-
converting enzyme inhibitors and beta-blockers may confer
some benefit but no proven therapy exists. We tested the
effects of an oral nutritional supplement in cachectic patients
with heart failure. This was a prospective, randomized,
double-blind, placebo-controlled pilot study which random-
ized 29 patients to a high-caloric (600 kcal) high-protein
(20 g) oral nutritional supplement or placebo for a duration
of 6 weeks in addition to the patients’ usual food intake. At
baseline, 6 weeks, and 18 weeks, we measured body
weight, quality of life, body composition, heart function,
laboratory parameters, and exercise performance. Edema-
free body weight increased in 19 of 20 patients receiving
intervention at 6 weeks and in 17 of 19 patients at 18 weeks
with an average weight gain of 2.0±1.7 kg (3.1±2.4%, p=
0.0001) and 2.3±3.1 kg (3.6±4.7%, p=0.007) at 6 and
18 weeks, respectively. Most of the weight gain was fat
tissue with an absolute gain of 1.5±1.7 kg (p=0.003) and
1.6±2.7 kg (p=0.008). A significant improvement in quality
of life and decrease in serum levels of tumor necrosis factor-α
were observed (p<0.05 for both). We demonstrated the
feasibility of oral nutritional supplement in cachectic patients
with heart failure and significant clinical benefit in terms of
body size and body composition, laboratory parameters, and
quality of life (www.clinicaltrials.gov identifier NCT00654719).
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During the natural progression of heart failure (HF), a number
of pathophysiological alterations lead to derangements in
metabolic and inflammatory systems [1, 2, 3, 4, 5]. From a
clinical perspective, whole body wasting and weight loss
develop, which may eventually engender cachexia [6, 7]. The
prevalence of cardiac cachexia in chronic HF is approximately
5% to 15% depending on its diagnostic criteria and HF
severity [8]. With mortality rates of up to 50% at 18 months
(in patients with at least 7.5% weight loss and a body mass
index <24.0 kg/m
2), the prognosis is grave and worse than
that of most cancers [9]. Previous studies in patients with
chronic HF demonstrated that treatment with angiotensin
converting enzyme (ACE) inhibitors reduced the risk of
weight loss [10] and treatment with beta-blockers induced
modest gain in edema-free weight [11]. There, however, is no
specific therapy for cachexia [12].
Nutritional aspects of the disease have not been studied
in details thus far; however, it is generally believed that
insufficient intake of protein and calorie may not necessarily
cause cardiac cachexia but may maintain its progression or
interfere with its correction [13]. Indeed, resting energy
expenditure is increased in patients with this perturbation
[14], but, total daily energy expenditure is reduced [15]. A
number of clinical–experimental approaches have been
tested including inhibition of cellular mechanisms of
wasting, reduction of energy expenditure, and increase in
energy supply, but no major benefit has been observed [16].
More practical approaches with oral nutritional supplements,
either alone or in conjunction with other adjunct measures,
have proven beneficial in some other chronic disease states
[17, 18, 19, 20], but to the best of our knowledge oral
nutritional interventions have not been tested in the setting of
HF cachexia.
We have performed a prospective, randomized, double-
blind, placebo-controlled pilot study to assess the effects of
high-calorie high-protein diets in addition to normal food
supply in patients with chronic HF and cachexia. We
hypothesized that a high-calorie high-protein oral nutritional
supplementation has beneficial effects on patients with
established cardiac cachexia, manifested by modest gain in
edema-free dry weight and through changes in plasma
cytokine profile and lipoproteins as well as improved health-
related quality of life.
2 Methods
2.1 Study design and participants
This was a prospective, randomized, double-blind, placebo-
controlled pilot study in the Silesian Center for Heart Diseases,
Zabrze,Poland.Patientsaged18–80yearswithstableHFNew
York Heart Association (NYHA) functional class II–IV, left
ventricular ejection fraction (LVEF) ≤30% and on a stable
medicationforatleast4weeks,attendingtheout-patientclinic,
were screened for edema-free weight loss >7.5% over a period
of at least 6 months. Patients with signs of acute inflammatory
processes, cancer, or severe chronic renal failure (serum
creatinine >250 μmol/l) were excluded. A total of 29 subjects
met the inclusion criteria and were eligible for randomization.
All were on standard medical therapy for HF including ACE
inhibitors, beta-blockers, spironolactone, and/or diuretics. The
study protocol complied with the principles outlined in the
Declaration of Helsinki. It was reviewed and approved by the
Ethics Committee of the Silesian Medical University (Kato-
wice, Poland) and all participants provided written informed
consent before inclusion. This study was registered under the
unique identifier NCT00654719 at www.clinicaltrials.gov.
2.2 Randomization and intervention
Upon enrolment, patients were randomized in a 3:1 fashion to
receive either a high-caloric, high-protein oral nutrition or a
matchingplacebofor 6weeks.Randomizationwas performed
blindly by the pharmacy department of the Silesian Center for
Heart Diseases. No physician and investigator involved in
clinical care or any laboratory assessment was aware of the
patients’ assignments until study completion at 18 weeks. All
patients were instructed to continue with their normal diet
duringthe 6weeks ofintervention.Patients inthe intervention
arm consumed additional 600 kcal per day as a commercially
available formulation NutriDrink
® (proteins 20 g, carbohy-
drates 72 g, fat 26 g; Nutricia Inc. Numico, Amsterdam, The
Netherlands—see Table 1), divided into two equal doses
given between main meals in order to avoid appetite
suppression. Patients in the placebo arm consumed matching
placebo (12 kcal/day) of similar taste and consistency to
assure for appropriate blinding.
2.3 Data collection
Patients were assessed at baseline, after 6 weeks of
treatment and 12 weeks after treatment (18 weeks from
study begin). The study protocol is outlined in Fig. 1.A t
each time point, we performed the following assessments:
(1) body weight was measured under identical conditions
and using the same weighing scale (B150L, Redwwag,
Zawiercie, Poland); (2) quality of life using the Minnesota
Living with Heart Failure Questionnaire (MLHFQ) in
which higher values indicate lower quality of life; (3) body
composition was measured using dual X-ray absorptiometry
(DEXA) with a pencil beam Lunar DRX-L device, (General
Electric, Brussels, Belgium); (4) serum level of inflammatory
markers and lipoproteins; (5) LVEF by an echocardiogram
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Packard, Andover, MA, USA); and (6) exercise capacity by
6-min walking-test and peak oxygen consumption during
exercise testing using Vmax-229 ergospirometry platform
(SensorMedics, Yorba Linda, CA, USA)
2.4 Laboratory measures
Blood samples were drawn at each visit after an overnight fast
fromanantecubitalveinandafter15minofrestinasemisupine
position. Upon blood collection, blood samples were centri-
fuged, and plasma and serum aliquots were immediately frozen
at −70°C. Cytokines were measured from serum samples using
high sensitivity test kits purchased from R&D Systems Europe,
(Abingden Oxon, UK). The lower limits of sensitivity were
0.106 pg/mL for tumor necrosis factor-α (TNFα), 0.77 pg/mL
for soluble TNFα receptor (TNFR-1), 0.6 pg/mL for soluble
TNFR-2. Plasma cholesterol, triglycerides, low-density lipo-
protein (LDL), and high density lipoprotein (HDL) cholesterol
were measuredusingcommerciallyavailablereagents provided
by Roche Diagnostics, Basel, Switzerland.
2.5 Statistical analysis
This was a pilot study with a randomization scheme favoring
allocation to active therapy to enable therapeutic support for
Signed informed consent
29 patients randomized
Ambulatory heart failure patients NYHA class II
LVEF   35%
Cardiac cachexia: 7.5% weight loss over 6 months
Placebo arm
6 patients
Placebo 12 kcal/day
6 weeks assessment
2     Death
1 Withdrew consent
Intervention arm
23 patients
Oral nutrition 600kcal/day
18 weeks assessment
1 Death
Heart transplantation 1
≥
≥
Fig. 1 Patient flow
Table 1 Detailed description of one package of nutridrink
Energy kJ/kcal 630/150
Proteins g 6
% of energy 16
Carbohydrates, including: g 18.4
Mono- and bisacharrides g 6.71
Lactose g <0.025
% of energy 49.1
Fats, including: g 5.8
Saturated fats g 0.6
% of energy 34.9
Soluble fiber g –
Minerals
Na mg 90
K mg 159
Cl mg 87
Ca mg 91
Pm g 7 8
Mg mg 23
Fe mg 2.4
Zn mg 1.8
Cu μg 270
Mn mg 0.5
F mg 0.15
Mo μg1 5
Se μg 8.6
Cr μg1 0
I μg2 0
Vitamins
A μg RE 123
Karotenoides mg 0.3
D μg 1.1
Em g α-TE 1.9
K μg8
Thiamin mg 0.23
Riboflavin mg 0.24
Niacin mg NE 2.7
Pantothenic acid mg 0.8
B6 mg 0.26
Folic acid μg4 0
B12 μg 0.32
Biotin μg6
Cm g 1 5
Other
Cholin mg 55
Osmolality mOsmol/l 4,552
J Cachexia Sarcopenia Muscle (2010) 1:35–42 37as many patients as possible. Due to the pilot character of
the study, the possible imbalances between the study groups
and the small size of the placebo group (and potential of
mitigated power), the primary analyses were restricted to the
patients in the active intervention group who completed
6 weeks therapy. The main purpose of the placebo group was
to keep investigators and patients uncertain about the
treatment allocation. Primary outcome measures were
edema-free body weight and health-related quality of life.
Secondary outcome measures were body composition, serum
levels of inflammatory markers and lipoproteins, LVEF, and
exercise capacity. Data are presented as mean value ±
standard deviation or as mean value ± standard error of
mean (SEM). Student t test for paired and unpaired samples,
Wilcoxon signed rank test and Mann–Whitney U test were
used as appropriate. Nominal variables were compared using
the Chi-square test or Fisher’s exact test as appropriate. A
p value <0.05 was considered significant. Statistical compar-
isons were carried out using Statistica v 6.0 (StatSoft Inc.
Tulsa, OK, USA).
3 Results
A total of 29 subjects were enrolled into the study: 23 were
started on oral nutritional support and six received placebo.
Patients were similar for age, sex, weight, body mass index,
HF etiology, co-morbidities, and medication for HF (Table 2).
No patient was lost to follow-up and most tolerated the oral
nutritional supplement. One patient withdrew consent after
1 week of intervention. Three patients died during the first
6 weeks (nutrition arm, 2; placebo arm, 1) and one patient on
nutritional supplementation died after 14 weeks. Among the
six subjects in the placebo group, we did not observe any
significant effect on outcome measures. In patients receiving
oral nutritional supplement, however, significant effects were
observed which are reported below.
Edema-free body weight increased in 19 out of 20
patients receiving intervention at 6 weeks and in 17 out of
19 at 18 weeks. An average weight gain was 2.0±1.7 kg
(3.1±2.4%) at 6 weeks (p=0.0001) and 2.3±3.1 kg (3.6±
4.7%) at 18 weeks (p=0.007)—Fig. 2. According to DEXA
Placebo n=6 Nutrition n=23 p value
Men [%] 83 74 0.65
Age [years] 49±12 52±10 0.53
Weight [kg] 62.8±7.5 63.9±10.5 0.81
Body mass index [kg/m
2] 21.3±1.4 21.9±2.2 0.53
Maximal body weight before heart failure [kg] 78±10 79±16 0.89
Percent decrease of body weight during heart failure [%] 18±5 18±5 1.0
Duration of heart failure [months] 43±25 77±74 0.28
Left ventricular ejection fraction [%] 24±5 25±10 0.33
NYHA class II/III/IV 3/3/0 5/14/1 0.34
Etiology of heart failure [%]
Ischemic 50 48 0.93
Postinflammatory 17 4 0.27
Idiopathic 17 8 0.52
Other 16 40 0.28
Co-morbidities [%]
Hypertension 67 39 0.23
Diabetes melitus 17 9 0.58
Hypercholesterolemia 67 48 0.41
Hypertriglicerydemia 17 17 1.0
Hyperuricemia 50 44 0.79
Atrial fibrillation 17 30 0.53
Permanent pacing 33 13 0.26
Pharmacotherapy [%]
ACE inhibitor 83 87 0.85
Beta-blockers 83 78 0.79
Spironolactone 83 96 0.27
Loop diuretics 100 91 0.51
Digoxin 83 83 1.0
Table 2 Patient characteristics
Numbers represent mean value
± standard deviation or percent
of patients
38 J Cachexia Sarcopenia Muscle (2010) 1:35–42scanning (Table 3), most of the weight gain was fat tissue.
Absolute gain in fat tissue was 1.5±1.7 kg (9.7±12.7%) at
6 weeks (p=0.003) and 1.6±2.7 kg (10.0±18.2%) at
18 weeks (p=0.008) and was present in 16 out of 19
patients. Lean tissue mass also increased after 6 weeks (p=
0.019) but the effect was not maintained at 18 weeks.
Self-reported quality of life as measured by MLHFQ
improved in all patients and the effect was preserved
throughout the study (Fig. 2). A constant increase in
distance walked in 6 min was observed (average increase
of 61 m) whereas the peak VO2 during treadmill exercise
testing and LVEF did not change significantly (Table 4).
Patient subjective perception of HF as assessed by NYHA
class was better in nine subjects with a significant overall
effect: 2.8±0.1 vs. 2.4±0.1, p=0.008. Compared to
baseline, none of patients experienced worsening of NYHA
class at any time point.
Oral nutritional supplement did not induce changes in
serum sodium, uric acid, and albumin concentrations. There
was a constant reduction of TNFα, soluble TNF-R1, and
TNF-R2 levels throughout the study and the decrease was
significant at 18 weeks when compared to baseline (Fig. 2
and Table 4). The serum lipoproteins total cholesterol and
LDL cholesterol increased in 13 and 14 patients, respec-
tively. From baseline to 18 weeks, a significant increase in
serum lipoprotein concentration was observed (Fig. 2 and
Table 4). Safety profile of oral nutritional supplement was
comparable to placebo and no major clinical complications
were recorded—Table 5.
4 Discussion
To our knowledge, this is the first interventional trial
evaluating the effect of an oral nutritional supplement in
cachectic patients with HF. The results of this pilot study
suggest that 6 weeks of high-calorie high-protein nutritional
support may have beneficial effects on dry body weight,
body composition, and quality of life. We also demonstrat-
ed increases in serum lipoproteins and a reduction in serum
TNFα levels.
Wasting in chronic disease states is on the rise and a
strong predictor of poor outcomes including high mortality.
Depending on the underlying disease and stage, 10–80% of
patients with chronic diseases can develop cachexia [21].
Currently, no definitive remedy exists to correct this fatal
condition [1]. Body wasting may be enhanced with in-
adequate food intake, thus an adequate diet should be a part
of daily routine management of chronic conditions. It is
therefore surprising that limited experience with simple
measures as diet counseling and nutritional support in
general and particularly in cardiac patients exists [19]. This
may be due to well-established risk factors for development
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Fig. 2 Results of assessments for body weight (a), quality of life (b),
TNFα (c), and total cholesterol (d) in patients with chronic HF and
cachexia receiving nutritional support for 6 weeks and being assessed
at baseline (N=23), week 6 (N=20) and week 18 (N=19). Numbers
and bars represent mean value ± SEM
J Cachexia Sarcopenia Muscle (2010) 1:35–42 39of clinically manifest cardiac disease which include in-
creased body size and elevated serum total/LDL cholesterol
that are partially driven by unhealthy diet, i.e., abundant
intake of high fat and caloric food. Once chronic disease has
developed, the risk factors seem not to be harmful anymore
and previously pathological levels confer prognostic benefit.
It has been suggested to term this phenomenon reverse
epidemiology, and it occurrence extends beyond cardiac
disease to fields of renal, pulmonary, musculoskeletal, and
malignant disease [22]. Screening for body wasting was
further hampered by lack of general definition for cachexia
and difficulties to perceive reduction of body weight in obese
or severely obese patients as grim prognostic sign. With
recently accepted consensus definition of cachexia [23],
particularly screening will be possible and we will be able to
obtain more reliable epidemiological data. When such
information will be at hand, design and conduction of trials
to pinpoint questions of interest in cachectic chronic disease
patients will be easier.
This study is the first to enter the arena of nutritional
support in cachectic HF patients. Although only 600
additional kilocalories per day (20%–25% of recommended
daily intake for individual patient) can seem trivial, a
significant benefit in terms of body weight and inflamma-
tory system was present. Even more important is the
finding that such effect continued or at least persisted after
termination of nutritional support and that patients experi-
enced benefit in all measured outcomes. The mechanisms
of cachexia are very complex and not entirely understood;
therefore we cannot conclude much about mechanistic
explanations of our results because this was beyond the
study design. Nonetheless, some speculations could be
derived in light of previous reports and when interpreting
the results in a concise and intelligent manner.
An increase in body weight after only 6 weeks of
additional 600 kcal/day in form of commercially available
product is clinically very relevant, particularly when ac-
counting for prior average 15 kg weight decrease from body
Baseline N=23 6 weeks N=20 p value
a 18 weeks N=19 p value
b
Fat tissue
Mass [kg] 15.55±0.72 16.59±0.87 0.003 17.23±0.98 0.008
Content [%] 25.5±1.2 26.9±1.1 0.02 27.7±1.4 0.04
Lean tissue
Mass [kg] 44.97±1.86 45.49±1.89 0.019 45.10±2.04 0.08
Content [%] 74.0±1.1 73.1±1.1 0.02 72.0±1.2 0.03
Fat tissue, arms, and legs
Mass [kg] 6.09±0.31 6.57±0.36 0.003 7.02±0.37 0.004
Lean tissue, arms, and legs
Mass [kg] 18.64±0.87 19.14±0.85 0.01 18.97±0.97 0.18
Table 3 Body composition
results in CHF patients with
cachexia in response to nutri-
tional therapy
Numbers represent mean value
± SEM
aBaseline vs 6 weeks
bBaseline vs 18 weeks
Table 4 Results on exercise capacity, echocardiography, and laboratory measures in heart failure patients with cachexia in response to nutritional
therapy
Baseline N=23 6 weeks N=20 p value
a 18 weeks N=19 p value
b
Peak VO2 [mL/kg/min] 14.5±0.6 14.9±0.7 0.32 14.2±0.8 0.74
6-min walk test [m] 366±23 410±24 0.02 433±25 0.08
Left ventricular ejection fraction [%] 25±10 25±9 0.47 24±8 0.79
Sodium [mmol/L] 140±1 140±1 0.98 139±1 0.79
Uric acid [mmol/L] 436±25 402±26 0.34 394±30 0.18
Creatinine [μmol/L] 95±6 93±6 0.88 97±7 0.90
Albumin [g/L] 43±1 44±1 0.84 45±1 0.70
LDL cholesterol [mmol/L] 3.0±0.2 3.3±0.2 0.12 3.7±0.3 0.006
HDL cholesterol [mmol/L] 1.5±0.1 1.6±0.1 0.40 1.5±0.1 0.52
Soluble TNF-R1 [pg/mL] 2.4±0.6 1.9±0.4 0.31 1.1±0.2 0.03
Soluble TNF-R2 [pg/mL] 5.4±0.7 5.0±0.9 0.96 3.2±0.9 0.02
Numbers represent mean value ± SEM
aBaseline vs 6 weeks
bBaseline vs 18 weeks
40 J Cachexia Sarcopenia Muscle (2010) 1:35–42weight when healthy. Weight stability or even weight gain
for some are of utmost importance in patients with chronic
disease. When body wasting or cachexia are present, a
reversal of weight reduction may improve the patients’
prognosis. In this context, treatment with ACE inhibitors
seems vital as they have been shown to prevent unintentional
weight loss [10]. It is not entirely irrelevant, which body
compartment is being wasted and which is being preserved.
According to previous findings [1], it seems that lean body
mass is associated with better quality of life whereas higher
fat content is linked to better survival [24]. Indeed, DEXA
scanning in our patients demonstrated clear increase of fat
mass and content while lean mass did not change signifi-
cantly. This in turn could then lead to less evident exercise
capacity improvement but the patients were found to be in
better clinical condition. Whether this translates into long-
term prognostic benefit remains to be investigated.
The reasons of reduced inflammation as documented by
decreases in TNFα and its soluble receptors cannot be clearly
explained from our data. In general, the higher plasma lipids in
our patients might have resulted from increased liver synthesis
of lipoproteins, decreased catabolism or both. It was repeatedly
shown in healthy humans that increased intake of fats raises
plasma cholesterol level, but entirely no data exist as to plasma
lipoprotein response to different fat intake in cardiac cachexia.
We feel this could be caused by reduced lipoprotein catabolism
which could be supported in several ways. Firstly, increased
intake of fats could have been associated with enhanced
buffering of endotoxins, and as recently demonstrated in
healthy humans [25] could have decreased catabolism of
lipoproteins. Secondly, oral nutritional supplement might have
increased lipids excretion with the bile resulting again in more
effective buffering of endotoxins. Thirdly, more frequent
stimulation of digestive tract with additional meals could
have activated the enteral nervous system to modulate local
mucosal immunity toward better protection against bacteria or
toxin translocation [26]. Unfortunately, we have not measured
levels of endotoxins or any gastric hormones to support such
hypothesis. Along with those changes in inflammatory
markers, a constant increase of total and LDL cholesterol
was observed. In patients with HF, higher total cholesterol is
associated with better survival [27]; thus, our findings might
bring additional clinical value for cachectic patients. Such
response fits well the endotoxin–lipoprotein hypothesis [28]
where lipoproteins reduce endotoxin burden through binding
and neutralization. Hence, the trigger for inflammatory system
is less pronounced and activation threshold is less often
reached. In other words, our data suggest that oral nutritional
supplement is safe in cardiac cachexia and nutritionally
induced lipid changes might be implicated in favorable
modification of inflammation. Same mechanisms may also
have ancillary effects on patient performance [29] and other
metabolic parameters [30, 31, 32].
4.1 Limitations
Our study with 29 patients has to be seen as a pilot trial in
which we wanted to prove the concept as reported for other
clinical conditions or situations. There, however, are some
caveats to be considered. A relatively high albumin concen-
tration at baseline is, in view of the advanced disease, likely
caused by aggressive diuretic treatment. A 3:1 randomization
was used to assure for an appropriate blinding and patient
assessment during the study rather than for a direct compar-
ison between intervention and placebo arm. With only six
patients in the control group, only results in the intervention
group could be interpreted as true effect beyond reasonable
doubt of effect by chance. We did not follow the caloric and
nutritional intake during the study. With commercially avail-
able product tested, which however is widely used as a nutri-
tional support in clinical practice, no conclusions can be made
about optimal dose and composition of nutritional support.
4.2 Clinical implications
This study demonstrated the feasibility of oral nutritional
supplement use in cachectic HF patients and suggests that
this may be a beneficial treatment approach in these patients.
In clinical practice, a nutritional assessment to screen for
malnourished or cachectic patients (or patients at risk) seems
warranted. When such individuals are identified, a nutritional
support may be appropriate (future studies need to confirm
our results). Nutritional therapy likely is particularly relevant
in the context of anabolic interventions, like physical
exercise and specific anabolic drug therapy (e.g., with
testosterone). It, however, remains unknown whether such
strategies would confer particular benefits for some patient
subgroups (e.g., those with enhanced inflammatory response)
Table 5 Adverse events
Placebo n=6 Nutrition n=23
Cardiovascular
Adverse event 3 9
Serious adverse event 3 8
Gastrointestinal
Adverse event 1 3
Serious adverse event 0 1
Pulmonary
Adverse event 1 2
Serious adverse event 0 1
Other
Adverse event 2 2
Serious adverse event 0 1
Numbers represent absolute number of patients
J Cachexia Sarcopenia Muscle (2010) 1:35–42 41and whether response is dose dependent. Before a more
general recommendation can be made, large-scale studies
addressing the many open issues have to be performed.
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